These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 7896946)
1. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946 [TBL] [Abstract][Full Text] [Related]
2. Increased levels of type I and III collagen and hyaluronan in scleroderma skin. Søndergaard K; Heickendorff L; Risteli L; Risteli J; Zachariae H; Stengaard-Pedersen K; Deleuran B Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294 [TBL] [Abstract][Full Text] [Related]
3. Photopheresis in systemic sclerosis: clinical and serological studies using markers of collagen metabolism. Zachariae H; Bjerring P; Heickendorff L; Møller B; Wallevik K; Angelo H Acta Derm Venereol; 1993 Oct; 73(5):356-61. PubMed ID: 7904402 [TBL] [Abstract][Full Text] [Related]
4. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy. Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217 [TBL] [Abstract][Full Text] [Related]
5. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Scheja A; Wildt M; Wollheim FA; Akesson A; Saxne T Rheumatology (Oxford); 2000 Oct; 39(10):1110-3. PubMed ID: 11035131 [TBL] [Abstract][Full Text] [Related]
6. Serum markers of type I collagen synthesis and degradation in amyotrophic lateral sclerosis. Ono S; Imai T; Shimizu N; Nakayama M; Yamano T; Tsumura M Eur Neurol; 2000; 44(1):49-56. PubMed ID: 10894996 [TBL] [Abstract][Full Text] [Related]
7. Serum markers of collagen synthesis and degradation in skin diseases. Altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment. Autio P; Risteli J; Kiistala U; Risteli L; Karvonen J; Oikarinen A Arch Dermatol Res; 1993; 285(6):322-7. PubMed ID: 8215582 [TBL] [Abstract][Full Text] [Related]
8. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels]. Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867 [TBL] [Abstract][Full Text] [Related]
9. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695 [TBL] [Abstract][Full Text] [Related]
10. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651 [TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S; Akakura K; Shimazaki J Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556 [TBL] [Abstract][Full Text] [Related]
13. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Scheja A; Hellmer G; Wollheim FA; Akesson A Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562 [TBL] [Abstract][Full Text] [Related]
14. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052 [TBL] [Abstract][Full Text] [Related]
15. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Oikarinen A; Autio P; Vuori J; Väänänen K; Risteli L; Kiistala U; Risteli J Br J Dermatol; 1992 Feb; 126(2):172-8. PubMed ID: 1536783 [TBL] [Abstract][Full Text] [Related]
16. Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen. Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS Clin Exp Rheumatol; 2000; 18(2):215-9. PubMed ID: 10812494 [TBL] [Abstract][Full Text] [Related]
17. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scheja A; Akesson A; Hørslev-Petersen K Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489 [TBL] [Abstract][Full Text] [Related]
18. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Zachariae H; Halkier-Sørensen L; Heickendorff L Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612 [TBL] [Abstract][Full Text] [Related]
19. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Hakala M; Aman S; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Risteli J Ann Rheum Dis; 1995 Nov; 54(11):886-90. PubMed ID: 7492237 [TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus. Villa-Manzano AI; Gamez-Nava JI; Salazar-Paramo M; Valera-Gonzalez IC; Garcia-Gonzalez A; Garcia-Gonzalez G; Morales-Romero J; Lopez-Olivo A; Galvan-Ramirez LM; Ruiz-Ruvalcaba R; Cardona-Muñoz EG; Gonzalez-Lopez L Rheumatol Int; 2006 Jun; 26(8):712-6. PubMed ID: 16231121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]